bezafibrate has been researched along with Dyslipidemias in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
| González-Ortiz, M; León-Martínez, JM; Martínez-Abundis, E; Pérez-Rubio, KG | 1 |
| Abe, K; Taneyama, T; Teramoto, T | 1 |
| Dohmen, K; Haruno, M; Tanaka, H | 1 |
| Gong, HR; Huang, WY; Li, XP; Zhao, SP | 1 |
| Hashizume, H; Horiguchi, N; Hosonuma, K; Kakizaki, S; Kusano, M; Sato, K; Yamada, M; Yamazaki, Y; Yanagisawa, M | 1 |
| Abe, K; Hirose, T; Taneyama, T; Teramoto, T | 1 |
| Kobayashi, J | 1 |
| Castellaneta, NM; Di Leo, A; Facciorusso, A; Licinio, R | 1 |
| Hosonuma, K; Kusano, M; Sato, K; Yamada, M | 1 |
| Bortoletto, MS; Petris, AJ; Souza, RK | 1 |
| Benderly, M; Goldbourt, U; Goldenberg, I | 2 |
| Hirano, K; Inomata, Y; Kobayashi, K; Miida, T; Nagasaka, H; Ota, A; Takatani, T; Takayanagi, M; Toyama-Nakagawa, Y; Tsukahara, H; Uemoto, S; Yorifuji, T | 1 |
| Fagundes, PP; Pinto, AS; Pinto, PA; Tebcherani, AJ; Valente, NY | 1 |
| Davidson, MH | 1 |
| Amita, M; Hara, S; Igarashi, H; Kurachi, H; Takahashi, T | 1 |
| Krysiak, R; Okopien, B | 1 |
| Daida, H; Shirai, K; Teramoto, T; Yamada, N | 1 |
| Aruanno, A; Buonomo, A; Nucera, E; Pecora, V; Schiavino, D | 1 |
| Constantinides, A; de Vries, R; Dullaart, RP; Gautier, T; Lagrost, L; Tselepis, AD; van Leeuwen, JJ; van Pelt, LJ | 1 |
| Fisman, EZ; Tenenbaum, A | 1 |
| Hayashi, S; Iwashima, Y; Kawano, Y; Nakamura, S; Ohta, Y; Yoshihara, F | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Patel, J | 1 |
| Vos, E | 1 |
| Harada, N; Kusuyama, A; Morishima, M; Nakaya, Y; Okada, K; Takahashi, A | 1 |
| Berneis, K; Rizzo, M | 1 |
4 review(s) available for bezafibrate and Dyslipidemias
| Article | Year |
|---|---|
Update on the use of fibrates: focus on bezafibrate.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Dyslipidemias; Humans; Hypolipidemic Agents; Primary Prevention | 2008 |
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Topics: Animals; Bezafibrate; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Treatment Outcome | 2007 |
7 trial(s) available for bezafibrate and Dyslipidemias
| Article | Year |
|---|---|
Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial.
Topics: Adult; Berberine; Bezafibrate; Dyslipidemias; Humans; Lipids; Middle Aged; Pilot Projects; Triglycerides | 2021 |
[The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia].
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
Topics: Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Creatinine; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Male; Middle Aged; Myalgia; Prognosis; Renal Insufficiency; Survival Rate; Time; Treatment Outcome; Ursodeoxycholic Acid | 2015 |
Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: a prospective pilot study of seven cases.
Topics: Adult; Bezafibrate; Clomiphene; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Female; Fertility Agents, Female; Humans; Hypolipidemic Agents; Infertility, Female; Ovulation Induction; Pilot Projects; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Prospective Studies | 2010 |
Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Bezafibrate; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Triglycerides | 2012 |
Effect of bezafibrate on office, home and ambulatory blood pressure in hypertensive patients with dyslipidemia.
Topics: Aged; Antihypertensive Agents; Bezafibrate; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Dyslipidemias; Female; Humans; Hypertension; Hypolipidemic Agents; Insulin; Insulin Resistance; Japan; Lipids; Male; Middle Aged; Office Visits; Predictive Value of Tests; Treatment Outcome | 2013 |
Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
Topics: Aged; Bezafibrate; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Treatment Outcome | 2008 |
18 other study(ies) available for bezafibrate and Dyslipidemias
| Article | Year |
|---|---|
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |
Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study.
Topics: Aged; Azetidines; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Japan; Lipids; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Time Factors; Treatment Outcome; Triglycerides | 2013 |
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; PPAR alpha; Prognosis; Renal Insufficiency; Retrospective Studies; Risk Factors; Uric Acid; Ursodeoxycholic Acid | 2013 |
Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
Topics: Aged; Antihypertensive Agents; Bezafibrate; Blood Glucose; Cholesterol, LDL; Diabetes Complications; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Sex Factors | 2015 |
How Does Bezafibrate Affect the Plasma LDL Cholesterol Levels?
Topics: Bezafibrate; Cholesterol, LDL; Diabetes Complications; Dyslipidemias; Female; Humans; Male | 2015 |
Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases?
Topics: Bezafibrate; Dyslipidemias; Female; Humans; Liver Cirrhosis, Biliary; Male; Myalgia; Renal Insufficiency; Ursodeoxycholic Acid | 2015 |
Response to Licinio et al.
Topics: Bezafibrate; Dyslipidemias; Female; Humans; Liver Cirrhosis, Biliary; Male; Myalgia; Renal Insufficiency; Ursodeoxycholic Acid | 2015 |
[Public sector participation in the supply of dyslipidemia medication in a population-based study].
Topics: Adult; Aged; Bezafibrate; Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Interviews as Topic; Male; Middle Aged; Prevalence; Public Sector; Simvastatin | 2016 |
Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis.
Topics: Adenosine Triphosphatases; Adult; ATP Binding Cassette Transporter, Subfamily B; Bezafibrate; Biopsy; Blotting, Western; Child; Child, Preschool; Cholestasis, Intrahepatic; Cholesterol; Dyslipidemias; Female; Histocytochemistry; Humans; Hypolipidemic Agents; Liver; Liver Function Tests; Male; Triglycerides | 2009 |
Eruptive xanthoma with unexpected granuloma annulare-like microscopic appearance: case report.
Topics: Adult; Bezafibrate; Diagnosis, Differential; Dyslipidemias; Granuloma; Humans; Hypolipidemic Agents; Male; Xanthomatosis | 2009 |
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
Topics: Animals; Betaine; Bezafibrate; Clofibric Acid; Dyslipidemias; Folic Acid; Homocysteine; Humans; Hypolipidemic Agents; Metabolic Syndrome | 2009 |
Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose.
Topics: Bezafibrate; Blood Glucose; Case-Control Studies; Cytokines; Dyslipidemias; Female; Humans; Inflammation; Male; Middle Aged; Models, Biological; Monocytes | 2011 |
Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study.
Topics: Aged; Bezafibrate; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glucose; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Japan; Lipid Metabolism; Male; Middle Aged; Prospective Studies; Retrospective Studies; Treatment Outcome; Triglycerides | 2012 |
Delayed-type hypersensitivity to fenofibrate.
Topics: Aged; Bezafibrate; Cross Reactions; Drug Hypersensitivity; Dyslipidemias; Emergency Medical Services; Female; Fenofibrate; Humans; Hypersensitivity, Delayed; Hypolipidemic Agents; Skin Tests | 2012 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Multitherapy for diabetes.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Pravastatin | 2006 |
Bezafibrate improves bacterial lipopolysaccharide-induced dyslipidemia and anorexia in rats.
Topics: Animals; Anorexia; Bezafibrate; Blood Glucose; Blood Proteins; Blotting, Northern; Body Weight; Dyslipidemias; Energy Metabolism; Hypolipidemic Agents; Ion Channels; Lipopolysaccharides; Lipoprotein Lipase; Male; Mitochondrial Proteins; Muscle Proteins; Organ Size; Rats; Rats, Wistar; RNA, Messenger; Uncoupling Protein 3 | 2007 |